The treatment of acute myeloid leukemia (AML) is a major clinical challenge, with patients often having poor prognoses, especially in subtypes with high-risk genetic profiles. PGAM5 plays a critical role in the progression of various malignancies; however, its biological function and underlying molecular mechanisms in AML remain unclear. The study aimed to systematically investigate the role and potential mechanisms of PGAM5 in AML. Bioinformatics analysis revealed that PGAM5 expression was significantly upregulated in AML patients compared with healthy controls, and high PGAM5 expression was closely associated with unfavorable prognosis. Further analysis suggested that PGAM5 may be related to the PI3K/AKT/mTOR signaling pathway. By establishing AML cell models with PGAM5 knockdown, functional experiments demonstrated that suppressing PGAM5 expression significantly arrested cell cycle progression, inhibited proliferation, and induced apoptosis. Mechanistic studies indicated that PGAM5 is closely associated with glycolytic metabolism in AML and enhances glycolytic flux through the transcription factor HIF-1α. Upon PGAM5 knockdown, AML cells exhibited significant reductions in glucose consumption, ATP production, and lactate output. Furthermore, treatment with the PI3K activator 740Y-P in PGAM5-knockdown cells provided additional evidence that PGAM5 plays a critical role in supporting AML cell proliferation and metabolic reprogramming, suggesting that PGAM5 may represent a candidate molecule for further functional investigation in AML. In summary, this study elucidates the key role of PGAM5 in metabolic remodeling in AML, suggesting its potential as a novel therapeutic target for AML treatment.

Background The application of guidance template in interstitial brachytherapy (ISBT) was expected to improve target coverage and sparing organs at risk for locally advanced cervical cancer (LACC). The purpose of this study was to compare dosimetric and procedural outcomes of template-guided ISBT against free-handed ISBT. Methods Consecutive patients with LACC were prospectively enrolled at Sichuan Cancer Hospital from February to September 2025. A novel 3D-printed free-assembled interstitial template (FAIT), featuring a tandem with optimized non-coplanar needle channels, was invented and utilized for ISBT. Each patient underwent both FAIT-guided and free-handed high-dose-rate ISBT within 3 days with a random sequence. Treatment plans were generated in the Oncentra planning system with a 600 cGy prescription, and dosimetric parameters including high-risk clinical target volume (HRCTV) D 90 , dose of organs at risk (OARs) (D 1cc and D 2cc for bladder, rectum, sigmoid and bowel) were extracted. The number of interstitial needles and implantation time were also recorded. Data were presented as mean ± standard deviation and compared using paired Student’s t -tests. Statistical significance was defined as P < 0.05. Results 55 patients received both FAIT-guided and free-handed ISBT procedures after pelvic external beam radiotherapy (EBRT) of 45-50.4 Gy with 25–28 fractions. Most patients were stage ⅡB (n = 34, 61.8%) and squamous cell carcinoma (n = 49, 89.1%), and mean post-EBRT HRCTV volume was 61.8 ± 21.3 cm 3 . There was no significant difference on the number of needles used in FAIT-guided and free-handed ISBTs (4.88 ± 0.90 vs. 4.76 ± 1.24, P = 0.30). FAIT guidance shortened implantation time (5.83 ± 1.93 vs 8.03 ± 2.71 min, P < 0.0001) and achieved higher HRCTV D90 (611.38 ± 35.12 vs 580.86 ± 64.65 cGy, P < 0.01), with similar OAR doses (P > 0.05). Conclusions Improved target volume dose coverage and shortened needle implantation time were achieved with the application of the novel 3D-printed FAIT in ISBT. This novel template had high clinical utility and was worthy of further promotion and application.

To noninvasively quantify the intrafraction motion of unresectable locally advanced colon cancer (UNLACC) via 1.5 T magnetic resonance imaging and linear accelerator (MR-linac) cine-MRI and assess the preliminary feasibility of translating motion envelopes into individualized, anisotropic residual-motion margins for stereotactic body radiotherapy (SBRT) workflow. This prospective, single‑centre, observational cross‑sectional study serves as a preliminary test to validate the workflow of a phase I single-arm clinical study and falls under the preliminary feasibility verification phase (Clinical Trials.gov NCT06244537; Initial Release Time: 01/25/2024). We first performed internal validation of a rolling–ball–based motion extraction (RBME) algorithm using a dynamic phantom on the same 1.5 T MR linac, which demonstrated negligible systematic error with a Bland‒Altman mean bias of 0.01 mm (standard deviation 0.49 mm) and 95

12125 Background: To explore the early intervention timing of recombinant human thrombopoietin (rhTPO) for cancer treatment-induced thrombocytopenia (CTIT) in cervical squamous cell carcinoma (CSCC) patients during concurrent chemoradiotherapy. Methods: Patients with stage I-IVa CSCC who developed CTIT during radical concurrent chemoradiotherapy were prospectively enrolled in our study. rhTPO intervention was used at the first presentation of G1 or G2 CTIT during concurrent chemotherapy respectively. The key indexes, including nadir platelet count, platelet recovery time, platelet transfusion and incidence of G3-5 CTIT were recorded in two groups. χ² test was used for the effective analysis, and univariate and multivariate analyses logistic regression analysis was used to predict the potential factors for the G3-5 CTIT. Results: From February 2021 to June 2024, 204 CSCC patients who developed CTIT during radical chemoradiotherapy at Sichuan Cancer Hospital were prospectively enrolled. 75 patients who occurred G1 and G2 CTIT at the first presentation during concurrent chemoradiotherapy received rhTPO intervention. They were included in the intent-to-treat (ITT) population analysis. According to the timing of the rhTPO intervention, the patients were divided into G1 group (100×10 9 /L>PLT>75×10 9 /L) and G2 group (75×10 9 /L>PLT>50×10 9 /L). For effective analysis, the nadir platelet count in G1 group was greater than that in G2 group (67 × 10 9 /L vs. 54 × 10 9 /L, p = 0.000), and the platelet recovery time in G1 group was shorter than that in G2 group (8 days vs. 14 days, p = 0.003). Moreover, patients in G1 group had a significantly lower incidence of G3-5 CTIT than that in G2 group (14.3% vs. 35%, p = 0.04). In two groups, only 1 patient in G2 group received 4 apheresis platelet units transfusion. Univariate and multivariate analysis showed the early intervention of the rhTPO was a substantial factor for decreasing the incidence of G3-5 CTIT. The sensitivity was 0.67 and the specificity was 0.74. Conclusions: For CSCC patients received with radical concurrent chemoradiotherapy, the early intervention of rhTPO was a substantial factor for decreasing the incidence of G3-5 CTIT. It could significantly improve the nadir platelet count, shorten the platelet recovery time, and reduce the incidence of G3-5 CTIT, thereby ensuring the uninterrupted continuation of treatment. Platelet recovery time and the degree of CTIT. Data Baseline platelet count(×10 9 /L) Days with platelet count recover ≥100×10 9 (Days) Minimal mean platelet count（×10 9 /L） Incidence of G3-5 CTIT(%) G1 group 172±64.92 8±5.86 67±15.81 14.3 G2 group 166±78.43 14±9.59 54±14.37 35 P value 0.76 0.003* 0.000* 0.04* *Statistically significant.

Interleukin 12 (IL-12) is a heterodimer consisting of 2 subunits, p35 and p40, with unique associations and interacting functions with its family members. IL-12 is one of the most important cytokines regulating the immune system response and is integral to adaptive immunity. IL-12 has shown marked therapeutic potential in a variety of tumor types. This review therefore summarizes the characteristics of IL-12 and its application in tumor treatment, focusing on its antitumor effects in colorectal cancer (CRC) and potential radiosensitization mechanisms. We aim to provide a current reference for IL-12 and other potential CRC treatment strategies.

In magnetic resonance- (MR-) based adaptive workflows for an MR-linac, the treatment plan is optimized and recalculated online using the daily MR images. The Unity MR-linac is supplied with a patient positioning device (ppd) using pelvic and abdomen thermoplastic masks attached to a board with high-density components. This study highlights the dosimetric effect of using this in such workflows when there are relative patient-ppd displacements, as these are not visualized on MR imaging and the treatment planning system assumes the patient is fixed relative to the ppd. The online adapted plans of two example rectum cancer patients treated at a Unity MR-linac were perturbed by introducing relative patient-ppd displacements, and the effect was evaluated on plan dosimetry. Forty-eight perturbed clinical adapted plans were recalculated, based on online MR-based synthetic computed tomography, and compared with the original plans, using dose-volume histogram parameters and gamma analysis. The target volume covered by the prescribed dose ( D_pre ) and by at least 107 D_pre varied up to − 1.87

PURPOSE:The response to neoadjuvant chemoradiotherapy (nCRT) varies among patients with locally advanced rectal cancer (LARC), and the treatment response of lymph nodes (LNs) to nCRT is critical in implementing a watch-and-wait strategy. A robust predictive model may help personalize treatment plans to increase the chance that patients achieve a complete response. This study investigated whether radiomics features based on prenCRT magnetic resonance imaging nodes could predict treatment response in preoperative LARC LNs. METHODS AND MATERIALS:The study included 78 patients with clinical stage T3-T4, N1-2, and M0 rectal adenocarcinoma who received long-course neoadjuvant radiotherapy before surgery. Pathologists evaluated 243 LNs, of which 173 and 70 were assigned to training and validation cohorts, respectively. For each LN, 3641 radiomics features were extracted from the region of interest in high-resolution T2WI magnetic resonance imaging before nCRT. The least absolute shrinkage and selection operator regression model was used for feature selection and radiomics signature building. A prediction model based on multivariate logistic analysis, combining radiomics signature and selected LN morphologic characteristics, was developed and visualized by drawing a nomogram. The model's performance was assessed by receiver operating characteristic curve analysis and calibration curves. RESULTS:The radiomics signature consists of 5 selected features that were effectively discriminated within the training cohort (area under the curve [AUC], 0.908; 95% CI, 0.857%-0.958%) and the validation cohort (AUC, 0.865; 95% CI, 0.757%-0.973%). The nomogram, which consisted of radiomics signature and LN morphologic characteristics (short-axis diameter and border contours), showed better calibration and discrimination in the training and validation cohorts (AUC, 0.925; 95% CI, 0.880%-0.969% and AUC, 0.918; 95% CI, 0.854%-0.983%, respectively). The decision curve analysis confirmed that the nomogram had the highest clinical utility. CONCLUSIONS:The nodal-based radiomics model effectively predicts LNs treatment response in patients with LARC after nCRT, which could help personalize treatment plans and guide the implementation of the watch-and-wait approach in these patients.

Magnetic resonance–guided adaptive radiotherapy (MRgART) represents the latest frontier in precision radiotherapy. It is distinguished from other modalities by the possibility of acquiring high-contrast soft tissue images, combined with the ability to recalculate and re-optimize the plan on the daily anatomy. The extensive database of available images offers ample scope for using disciplines such as radiomics to try to correlate features and outcomes. This study aimed to correlate the change of radiomics feature along the treatment to pathological complete response (pCR) for locally advanced rectal cancer (LARC) patients. Twenty-eight LARC patients undergoing neoadjuvant chemoradiotherapy (nCRT) with a short course (25 Gy, 5 Gy × 5f) MRgART at 1.5 Tesla MR-Linac were enrolled. The T2-weighted images acquired at each fraction, corresponding target delineation, pCR result of the surgical specimen, and clinical variables were collected. Seven families of features [First Order, Shape, Gray-level Co-occurrence Matrix (GLCM), Gray-level Dependence Matrix (GLDM), Gray-level Run Length Matrix (GLRLM), Gray-level Size Zone Matrix (GLSZM), and Neighborhood Gray Tone Difference Matrix (NGTDM)] were extracted, and delta features were calculated from the ratio of features of each successive fraction to those of the first fraction. Mann-Whitney U test and LASSO were utilized to reduce the dimension of features and select those features that are most significant to pCR. At last, the radiomics signatures were established by linear regression with the final set of features and their coefficients. A total of 581 radiomics features were extracted, and 2,324 delta features were calculated for each patient. Nineteen features and delta features, and one clinical variable (cN) were significant (p< 0.05) to pCR; seven predictive features were further selected and included in the linear regression to construct the radiomics signature significantly discriminating pCR and non-pCR groups (p< 0.05). Delta features based on MRI images acquired during a short course MRgART could potentially be used to predict treatment response in LARC patients undergoing nCRT.

Abstract Background Magnetic resonance-guided adaptive radiotherapy (MRgART) treatment sessions at MR-Linac are time-consuming and changes in organs at risk volumes can impact the treatment dosimetry. This study aims to evaluate the feasibility to control bladder filling during the rectum MRgART online session and its effectiveness on plan dosimetry. Methods A total of 109 online adaptive sessions of 24 rectum cancer patients treated at Unity 1.5 T MR-Linac with a short course radiotherapy (25 Gy, 5 Gy × 5) for whom the adaptive plan was optimized and recalculated online based on the daily magnetic resonance imaging (MRI) were analysed. Patients were fitted with a bladder catheter to control bladder filling; the bladder is emptied and then partially filled with a known amount of saline at the beginning and end of the online session. A first MRI ( $${\mathrm{MRI}}_{\mathrm{i}}$$ MRI i ) acquired at the beginning of the session was used for plan adaptation and the second ( $${\mathrm{MRI}}_{\mathrm{f}}$$ MRI f ) was acquired while approving the adapted plan and rigidly registered with the first to ensure the appropriateness of the isodoses on the ongoing delivery treatment. For each fraction, the time interval between the two MRIs and potential bladder changes were assessed with independent metrics, and the impact on the plan dosimetry was evaluated by comparing target and organs at risk dose volume histogram cut-off points of the plan adapted on $${\mathrm{MRI}}_{\mathrm{i}}$$ MRI i and recalculated on $${\mathrm{MRI}}_{\mathrm{f}}$$ MRI f . Results Median bladder volume variations, DSC, and HD of 8.17%, 0.922, and 2.92 mm were registered within a median time of 38 min between $${\mathrm{MRI}}_{\mathrm{i}}$$ MRI i and $${\mathrm{MRI}}_{\mathrm{f}}$$ MRI f ; dosimetric differences < 0.65% were registered for target coverage, and < 0.5% for bladder, small bowel and femoral heads constraints, with a p value > 0.05. Conclusion The use of a bladder filling control procedure can help ensure the dosimetric accuracy of the online adapted treatment delivered.

Abstract Background Predicting pathological complete response (pCR) in patients affected by locally advanced rectal cancer (LARC) who undergo neoadjuvant chemoradiotherapy (nCRT) is a challenging field of investigation, but many of the published models are burdened by a lack of reliable external validation. Aim of this study was to evaluate the applicability of a magnetic resonance imaging (MRI) radiomic-based pCR model developed and validated in Europe, to a different cohort of patients from an intercontinental cancer center. Methods The original model was based on two clinical and two radiomics features extracted from T2-weighted 1.5 T MRI of 161 LARC patients acquired before nCRT, considered as training set. Such model is here validated using the T2-w 1.5 and 3 T staging MRI of 59 LARC patients with different clinical characteristics consecutively treated in mainland Chinese cancer center from March 2017 to January 2018. Model performance were evaluated in terms of area under the receiver operator characteristics curve (AUC) and relative parameters, such as accuracy, specificity, negative and positive predictive value (NPV and PPV). Results An AUC of 0.83 (CI 95%, 0.71–0.96) was achieved for the intercontinental cohort versus a value of 0.75 (CI 95%, 0.61–0.88) at the external validation step reported in the original experience. Considering the best cut-off threshold identified in the first experience (0.26), the following predictive performance were obtained: 0.65 as accuracy, 0.64 as specificity, 0.70 as sensitivity, 0.91 as NPV and 0.28 as PPV. Conclusions Despite the introduction of significant different factors, the proposed model appeared to be replicable on a real-world data extra-European patients’ cohort, achieving a TRIPOD 4 level.

Neoadjuvant chemoradiotherapy (nCRT) and total rectal mesenteric excision are the main standards of treatment for locally advanced rectal cancer (LARC). Lymph node regression grade (LRG) is an indicator of prognosis and response to preoperative nCRT based on postsurgical metastatic lymph node pathology. Common histopathological findings in metastatic lymph nodes after nCRT include necrosis, hemorrhage, nodular fibrosis, foamy histiocytes, cystic cell reactions, areas of hyalinosis, residual cancer cells, and pools of mucin. A number of LRG systems designed to classify the amount of lymph node regression after nCRT is mainly concerned with the relationship between residual cancer cells and regressive fibrosis and with estimating the number of lymph nodes existing with residual cancer cells. LRG offers significant prognostic information, and in most cases, LRG after nCRT correlates with patient outcomes. In this review, we describe the systematic classification of LRG after nCRT, patient prognosis, the correlation with tumor regression grade, and the typical histopathological findings of lymph nodes. This work may serve as a reference to help predict the clinical complete response and determine lymph node regression in patients based on preservation strategies, allowing for the formulation of more accurate treatment strategies for LARC patients, which has important clinical significance and scientific value.

Abstract Purpose This study aims to further enhance a validated radiomics-based model for predicting pathologic complete response (pCR) after chemo‑radiotherapy in locally advanced rectal cancer (LARC) for use in clinical practice. Methods A generalized linear model (GLM) to predict pCR in LARC patients previously trained in Europe and validated with an external inter-continental cohort (59 patients), was first examined with further 88 intercontinental patient datasets to assess its reproducibility; then new radiomics and clinical features, and validation methods were investigated to build a new model for enhancing the pCR prediction for patients admitted to our department. The patients were divided into training group (75%) and validation group (25%) according to their demographic. The least absolute shrinkage and selection operator (LASSO) logistic regression was used to reduce the dimensionality of the extracted features of the training group and select the optimal ones; the performance of the reference GLM and enhanced models was compared through the area under curve (AUC) of the receiver operating characteristics. Results The value of AUC of the reference model was 0.831 (95% CI, 0.701–0.961), and 0.828 (95% CI, 0.700–0.956) in the original and new validation cohorts, respectively, showing a reproducibility in the applicability of the GLM model. Eight features were found to be significant with LASSO and used to establish an enhanced model. The AUC of the enhanced model of 0.926 (95% CI, 0.859–0.993) for training, and 0.926 (95% CI, 0.767–1.00) for the validation group shows better performance than the reference model. Conclusions The GLM model shows good reproducibility in predicting pCR in LARC; the enhanced model has the potential to improve prediction accuracy and may be a candidate in clinical practice.

川崎病(Kawasaki disease,KD)是一种以全身血管炎为主要表现的小儿发热自限性疾病,常常累及冠状动脉导致不同程度的血管病变,如引起冠状动脉扩张、冠状动脉瘤形成等损害.KD病因至今不明,其诊断主要依靠典型临床表现和超声心动图检查,急性期治疗目的 在于控制全身炎症以及减少冠状动脉病变的发生.早期诊断并及时静注人免疫球蛋白(IVIG)治疗,可明显降低冠状动脉损害的发生率.本文就川崎病的研究概况及诊治进展进行综述,旨在为临床KD的诊治提供参考.

Recently,two studies published in Nature identified genetic changes in the nuclear receptor-binding SET domain protein(NSD)family of histone methyltransferases as oncogenic drivers in some malignancies,and revealed the nucleosome-based recogni-tion and histone-modification mechanisms of NSD2 and NSD3.

Background PD-1 inhibitor have demonstrated significant efficacy in the treatment of recurrent or refractory gynecologic cancer. However, the clinical data among Chinese patients is still limited. In this study, the efficacy and safety of toripalimab in the treatment of recurrent or refractory gynecologic cancer was evaluated. Methods A retrospective analysis of patients with recurrent or refractory gynecologic cancer who were treated with toripalimab in Sichuan Cancer Hospital from September 2019 to December 2020 was performed. The treatment regimens included toripalimab monotherapy or toripalimab in combination with other therapies (eg, radiotherapy, chemotherapy, targeted therapy). Statistical analysis of the objective response rate(ORR), progression-free survival(PFS), and toxicity after the treatment was carried out. Results In total 18 recurrent or refractory gynecologic cancer patients who received toripalimab were reviewed in this study, including 12 patients with cervical cancer, 3 patients with vulvar cancer, 2 patients with uterine tumor, and 1 patient with pelvic wall squamous cell carcinoma. The patients previously received ≤1 line of treatment for advanced or recurrent cancer. The median follow-up period was 8 months [3.17–19.27 months]. The overall ORR was 33.3% (6/18), DCR was 77.8% (14/18), and median PFS was 8 months [95% CI: 6.53-NA].For patients who received toripalimab as monotherapy, the ORR was 22.2% (2/9), DCR was 66.7% (6/9), and median PFS was 11.8 months (95% CI: 6.53-NA). For patients treated with toripalimab combination therapy, the ORR was 44.4% (4/9), DCR was 88.9% (8/9), and median PFS was 8 months (95% CI: 6.23-NA). Select treatment related AEs (TRAEs) of any grade were observed in 46.7% (7/18) patients. Grade 3 hepatotoxicity was recorded in 1 case. There was no treatment-related deaths. Conclusions Toripalimab as monotherapy or Toripalimab combining with traditional anti-cancer therapy shows promising efficacy and acceptable toxicity in Chinese recurrent or refractory gynecologic cancer

AIMS:Prostate cancer (PCa) is the most common type of cancer and a major cause of death in men worldwide. Aberrant Androgen receptor (AR) and PI3K-AKT signaling are very frequent in PCa patients and, therefore, considered as therapeutic targets in the clinic. Sin1 is an essential component of mTORC2 complex, which determines full AKT activation and PCa development in PTEN-/- mice. Here we examined the role of Sin1 in human PCa cell lines and respective tumor samples.MAIN METHODS:Western blotting and immunohistochemistry (IHC) were performed to analyze the expression of Sin1-mTORC2-AKT related proteins in human PCa cells, as well as prostate tumors and normal tissue counterparts. Cell viability and invasion assays were also pursued in the presence or not of Sin1 in PCa cells. Immunoprecipitation assays were additionally carried out to examine the interaction of Sin1 with AR.KEY FINDINGS:We have presently demonstrated that high levels of Sin1 expression in human PCa tissues correlate with cancer progression. Sin1-mediated cell proliferation and invasion of PCa cells occurs by regulating mTORC2-AKT signaling, epithelial-mesenchymal transition and matrix metalloproteinases. Moreover, androgens are able to induce Sin1 expression, which is further translocated to the nucleus of PCa cells. Finally, Sin1 interacts with AR to suppress its transcriptional activity.SIGNIFICANCE:Taken together, these data indicate that both Sin1-mediated mTORC2-AKT signaling and Sin1-AR interaction regulate PCa development. Hence, Sin1 may be considered a novel biomarker of PCa progression.

Background Volumetric modulated arc therapy (VMAT) adopted in post-mastectomy radiation therapy (PMRT) has the capacity to achieve highly conformal dose distributions. The research aims to evaluate the impact of positioning errors in the dosimetry of VMAT left-sided PMRT. Methods A total of 18 perturbations where introduced in 11 VMAT treatment plans that shifted the isocenter from its reference position of 3, 5, 10 mm in six directions. The thoracic wall and supraclavicular clinical target volumes (CTVs), the heart and the left lung dose volume histograms (DVHs) of 198 perturbed plans were calculated. The absolute differences ( ∆ ) of the mean dose (Dm) and DVH endpoints Vx and Dy (percentage volume receiving x Gy, and dose covering y% of the volume, respectively) were used to compare the dosimetry of the reference vs perturbed plans. Results Isocenter shifts in the anterior and lateral directions lead to maximum disagreement between the CTVs dosimetry of perturbed vs reference plans. Isocenter shifts of 10 mm shown a decrease of D95, D98 and Dm of 12.8, 18.0, and 2.9% respectively, for the CTVs. For 5 mm isocenter shifts, these differences decreased to 3.2, 5.2, and 0.9%, respectively, and for 3 mm shifts to 1.0, 1.7, and 0.6%, respectively. For the organs at risk (OARs), only isocenter shifts in the right, posterior and inferior directions worsen the plan dosimetry, nevertheless not negligible lung ∆ V20 of + 2.6%, and heart ∆ V25 of + 1.6% persist for 3 mm shifts. Conclusions Inaccuracy in isocenter positioning for VMAT left-sided PMRT irradiation may impact the dosimetry of the CTVs and OARs to a different extent, depending on the directions and magnitude of the perturbation. The acquired information could be useful for planning strategies to guarantee the accuracy of the treatment delivered.

Objectives: To evaluate the difference of YAP-positive expression between GC and adjacent tissues, as well as the association of elevated YAP expression with clinicopathological features of GC. Methods: PubMed, Embase, Web of Science databases and the Chinese National Knowledge Infrastructure (CNKI) were searched from inception up to December 2018. The pooled ORs and corresponding 95% CIs were used to assess the strength of association. The heterogeneity among eligible studies was evaluated by the Q-test and I2 values. The sensitivity analysis was performed by sequential omission of individual studies. Moreover, Begg’s test and Egger’s test were used to evaluate publication bias. Results: A total of 2229 patients from 16 studies were included in this meta-analysis. The results showed that positive YAP expression was closely correlated with GC but not adjacent non-tumor tissue (OR = 8.08, 95% CI = 4.41 - 14.80). Additionally, YAP overexpression was found to be associated with more advanced TNM stage (OR = 2.68, 95% CI = 1.61 - 4.48), deeper invasion depth (OR = 2.05, 95% CI = 1.32 - 3.19), and lymph node metastasis (OR = 1.95, 95% CI = 1.29 - 2.96). No significant correlation was observed between YAP overexpression and degree of differentiation (OR = 1.17, 95% CI = 0.63 - 2.16), as well as gender of patients (OR = 1.12, 95% CI = 0.91 - 1.37) or tumor size (OR = 1.11, 95% CI = 0.82 - 1.49) of gastric cancer. Conclusions: This meta-analysis demonstrated that YAP might be a promising diagnostic marker and even a therapeutic target for gastric cancer.

Abstract Systemic inflammatory response markers are associated with poor survival in many types of malignances. This study aimed to evaluate the prognostic value of preoperative neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and C-reactive protein (CRP) in patients with non-small cell lung cancer (NSCLC). We retrospectively evaluated 254 NSCLC patients who underwent radical surgery between January 2012 and April 2014 in the Sichuan Provincial Cancer Hospital. The cut-off values of NLR, PLR, LMR, and CRP were determined according to the receiver operating characteristic curve, and the correlation of NLR, PLR, LMR, and CRP with prognosis was analyzed based on the cut-off value. The cut-off value for NLR, PLR, LMR, and CRP were 3.18, 122, 4.04, and 8.8, respectively. Univariate analysis showed that age (P = .022), tumor-node-metastasis (TNM) stage (P < .001), T stage (P = .001), and N stage (P < .001) were significantly correlated with disease-free survival (DFS), while age (P = .011), TNM stage (P < .001), T stage (P = .008), N stage (P < .001), and PLR (P = .001) were significantly correlated with overall survival (OS). In multivariate analysis, age (hazard ratio [HR]: 1.564, 95% confidence interval [CI]: 1.087–2.252, P = .016) and TNM stage (HR: 1.704, 95% CI: 1.061–2.735, P = .027) remained independent risk factors affecting DFS, while age (HR: 1.721, 95% CI: 1.153–2.567, P = .008), TNM stage (HR: 2.198, 95% CI: 1.263–3.824, P = .005), and PLR (HR: 1.850, 95% CI: 1.246–2.746, P = .002) were independent risk factors affecting OS. The preoperative PLR is superior to NLR, LMR, and CRP as a biomarker for evaluating the prognosis of patients undergoing curative surgery for NSCLC.